Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established....
Guardat en:
| Format: | Online |
|---|---|
| Idioma: | anglès |
| Publicat: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Matèries: | |
| Accés en línia: | ONIX_20221025_9783036552217_68 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
| _version_ | 1869525656747900928 |
|---|---|
| collection | Directory of Open Access Books |
| description | Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges. |
| format | Online |
| id | doab-20.500.12854ir-93214 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-932142024-04-09T23:16:13Z Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action Allison, Simon J microtubule acetylation triple-negative breast cancer anti-cancer agent apoptosis K562 8-hydroxydaidzein autophagy BCR-ABL MAPK NF-κB c-myc RNA interference siRNA oncogene gene silencing expression nanosystems Cytochrome P450 CYP1A1 CYP1B1 CYP2W1 breast cancer prodrug bioprecursor duocarmycin phortress AQ4N 5-FU resistance colorectal cancer drug repurposing Genomics of Drug Sensitivity in Cancer Connectivity Map anticancer drug B-lactam steroid alkylators synthetic lethality poly (ADP-ribose) polymerase inhibitors ovarian cancer hybrid steroidal alkylating agents migration invasion glioblastoma CCN1 mesenchymal–amoeboid transition biomarker HepG2 Huh7 isatin sulfonamides angiogenesis cancer hallmarks molecular docking EGFR tyrosine kinase inhibitor photon upconversion triplet-triplet annihilation in vivo imaging PLGA nanoparticles affibody molecule human epidermal growth factor receptor 3 (HER3) BxPC-3 emtansine DM1 albumin binding domain affibody drug conjugate (AffiDC) n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues::TBX History of engineering and technology Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges. 2022-10-25T09:02:29Z 2022-10-25T09:02:29Z 2022 book ONIX_20221025_9783036552217_68 9783036552217 9783036552224 https://directory.doabooks.org/handle/20.500.12854/93214 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/6112 https://mdpi.com/books/pdfview/book/6112 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-5222-4 10.3390/books978-3-0365-5222-4 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036552217 9783036552224 206 open access |
| spellingShingle | microtubule acetylation triple-negative breast cancer anti-cancer agent apoptosis K562 8-hydroxydaidzein autophagy BCR-ABL MAPK NF-κB c-myc RNA interference siRNA oncogene gene silencing expression nanosystems Cytochrome P450 CYP1A1 CYP1B1 CYP2W1 breast cancer prodrug bioprecursor duocarmycin phortress AQ4N 5-FU resistance colorectal cancer drug repurposing Genomics of Drug Sensitivity in Cancer Connectivity Map anticancer drug B-lactam steroid alkylators synthetic lethality poly (ADP-ribose) polymerase inhibitors ovarian cancer hybrid steroidal alkylating agents migration invasion glioblastoma CCN1 mesenchymal–amoeboid transition biomarker HepG2 Huh7 isatin sulfonamides angiogenesis cancer hallmarks molecular docking EGFR tyrosine kinase inhibitor photon upconversion triplet-triplet annihilation in vivo imaging PLGA nanoparticles affibody molecule human epidermal growth factor receptor 3 (HER3) BxPC-3 emtansine DM1 albumin binding domain affibody drug conjugate (AffiDC) n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues::TBX History of engineering and technology Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
| title | Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
| title_full | Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
| title_fullStr | Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
| title_full_unstemmed | Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
| title_short | Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
| title_sort | novel anti cancer agents and cellular targets and their mechanism s of action |
| topic | microtubule acetylation triple-negative breast cancer anti-cancer agent apoptosis K562 8-hydroxydaidzein autophagy BCR-ABL MAPK NF-κB c-myc RNA interference siRNA oncogene gene silencing expression nanosystems Cytochrome P450 CYP1A1 CYP1B1 CYP2W1 breast cancer prodrug bioprecursor duocarmycin phortress AQ4N 5-FU resistance colorectal cancer drug repurposing Genomics of Drug Sensitivity in Cancer Connectivity Map anticancer drug B-lactam steroid alkylators synthetic lethality poly (ADP-ribose) polymerase inhibitors ovarian cancer hybrid steroidal alkylating agents migration invasion glioblastoma CCN1 mesenchymal–amoeboid transition biomarker HepG2 Huh7 isatin sulfonamides angiogenesis cancer hallmarks molecular docking EGFR tyrosine kinase inhibitor photon upconversion triplet-triplet annihilation in vivo imaging PLGA nanoparticles affibody molecule human epidermal growth factor receptor 3 (HER3) BxPC-3 emtansine DM1 albumin binding domain affibody drug conjugate (AffiDC) n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues::TBX History of engineering and technology |
| topic_facet | microtubule acetylation triple-negative breast cancer anti-cancer agent apoptosis K562 8-hydroxydaidzein autophagy BCR-ABL MAPK NF-κB c-myc RNA interference siRNA oncogene gene silencing expression nanosystems Cytochrome P450 CYP1A1 CYP1B1 CYP2W1 breast cancer prodrug bioprecursor duocarmycin phortress AQ4N 5-FU resistance colorectal cancer drug repurposing Genomics of Drug Sensitivity in Cancer Connectivity Map anticancer drug B-lactam steroid alkylators synthetic lethality poly (ADP-ribose) polymerase inhibitors ovarian cancer hybrid steroidal alkylating agents migration invasion glioblastoma CCN1 mesenchymal–amoeboid transition biomarker HepG2 Huh7 isatin sulfonamides angiogenesis cancer hallmarks molecular docking EGFR tyrosine kinase inhibitor photon upconversion triplet-triplet annihilation in vivo imaging PLGA nanoparticles affibody molecule human epidermal growth factor receptor 3 (HER3) BxPC-3 emtansine DM1 albumin binding domain affibody drug conjugate (AffiDC) n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues::TBX History of engineering and technology |
| url | ONIX_20221025_9783036552217_68 |